Article info

Download PDFPDF

Still early to define a clear role of antimalarial drugs for COVID-19 in patients with rheumatic disease. Response to: ‘Hydroxychloroquine reduces the risk of covid-19 in patients with rheumatic diseases: myth or reality?’ by Xie et al
Free

Authors

  1. Correspondence to Dionicio Angel Galarza-Delgado, Servicio de Reumatología, Hospital Universitario Dr Jose Eleuterio Gonzalez, Monterrey 64460, Mexico; dgalarza{at}medicinauanl.mx
View Full Text

Citation

Gamboa-Alonso CM, Figueroa-Parra G, Galarza-Delgado DA
Still early to define a clear role of antimalarial drugs for COVID-19 in patients with rheumatic disease. Response to: ‘Hydroxychloroquine reduces the risk of covid-19 in patients with rheumatic diseases: myth or reality?’ by Xie et al

Publication history

  • Received June 9, 2020
  • Revised June 10, 2020
  • Accepted June 12, 2020
  • First published June 22, 2020.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.